Cardiff Oncology (CRDF) 10-Q 9 Nov 16 2016 Q3 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	9 Months Ended
	Sep. 30, 2016	Oct. 31, 2016
Document and Entity Information
Entity Registrant Name	Trovagene, Inc.
Entity Central Index Key	1,213,037
Document Type	10-Q
Document Period End Date	Sep. 30, 2016
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity Current Reporting Status	Yes
Entity Filer Category	Accelerated Filer
Entity Common Stock, Shares Outstanding		30,615,406
Document Fiscal Year Focus	2,016
Document Fiscal Period Focus	Q3

CONDENSED CONSOLIDATED BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)	Sep. 30, 2016	Dec. 31, 2015
Current assets:
Cash and cash equivalents	$ 22,569,107	$ 67,493,047
Short-term investments	24,376,904	0
Accounts receivable	85,152	98,736
Prepaid expenses and other assets	946,388	789,285
Total current assets	47,977,551	68,381,068
Property and equipment, net	4,654,876	2,690,579
Other assets	371,243	374,004
Total Assets	53,003,670	71,445,651
Current liabilities:
Accounts payable	925,173	1,040,868
Accrued expenses	4,558,809	1,903,797
Deferred rent	279,710	30,614
Current portion of long-term debt	801,024	5,225,818
Total current liabilities	6,564,716	8,201,097
Long-term debt, less current portion	15,595,400	11,246,188
Derivative financial instruments - warrants	2,622,243	3,297,077
Deferred rent, net of current portion	1,446,912	0
Total Liabilities	26,229,271	22,744,362
Commitments and contingencies (Note 9)
Stockholders’ equity
Preferred stock, $0.001 par value, 20,000,000 shares authorized; 60,600 shares outstanding at September 30, 2016 and December 31, 2015; designated as Series A Convertible Preferred Stock with liquidation preference of $606,000 at September 30, 2016 and December 31, 2015	60	60
Common stock, $0.0001 par value, 150,000,000 shares authorized; 30,599,140 and 29,737,601 shares issued and outstanding at September 30, 2016 and December 31, 2015, respectively	3,060	2,974
Additional paid-in capital	166,337,512	157,585,498
Accumulated other comprehensive loss	(4,742)	0
Accumulated deficit	(139,561,491)	(108,887,243)
Total stockholders’ equity	26,774,399	48,701,289
Total liabilities and stockholders’ equity	$ 53,003,670	$ 71,445,651

CONDENSED CONSOLIDATED BALANCE3

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($)	Sep. 30, 2016	Dec. 31, 2015
Statement of Financial Position [Abstract]
Preferred stock, par value (in USD per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized	20,000,000	20,000,000
Preferred stock, shares outstanding	60,600	60,600
Series A Convertible Preferred Stock, liquidation preference (in dollars)	$ 606,000	$ 606,000
Common stock, par value (in USD per share)	$ 0.0001	$ 0.0001
Common stock, shares authorized	150,000,000	150,000,000
Common stock, shares issued	30,599,140	29,737,601
Common stock, shares outstanding	30,599,140	29,737,601

CONDENSED CONSOLIDATED STATEMEN

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Income Statement [Abstract]
Royalties	$ 47,236	$ 51,301	$ 207,869	$ 222,931
Diagnostic services	37,978	6,026	69,558	10,712
Clinical research services	3,900	0	35,573	0
Total revenues	89,114	57,327	313,000	233,643
Costs and expenses:
Cost of revenues	424,559	173,537	1,143,293	429,992
Research and development	3,937,398	2,546,533	11,221,876	7,428,349
Selling and marketing	2,940,862	1,798,263	9,127,450	4,508,766
General and administrative	2,710,782	1,948,546	9,183,761	5,756,047
Total operating expenses	10,013,601	6,466,879	30,676,380	18,123,154
Loss from operations	(9,924,487)	(6,409,552)	(30,363,380)	(17,889,511)
Net interest expense	(354,993)	(335,359)	(967,522)	(1,100,080)
Gain (loss) from change in fair value of derivative financial instruments — warrants	88,208	4,017,212	674,834	(1,105,270)
Other income (loss), net	0	(8,130)	0	4,617
Net loss	(10,191,272)	(2,735,829)	(30,656,068)	(20,090,244)
Preferred stock dividend	(6,060)	(6,060)	(18,180)	(18,180)
Net loss attributable to common stockholders	$ (10,197,332)	$ (2,741,889)	$ (30,674,248)	$ (20,108,424)
Net loss per common share - basic (in USD per share)	$ (0.34)	$ (0.10)	$ (1.02)	$ (0.80)
Net loss per common share - diluted (in USD per share)	$ (0.34)	$ (0.23)	$ (1.04)	$ (0.96)
Weighted average shares outstanding — basic	30,339,774	28,560,211	30,018,841	25,014,966
Weighted average shares outstanding — diluted	30,339,774	29,128,235	30,136,572	25,204,307

CONDENSED CONSOLIDATED STATEME5

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) Statement - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Statement of Comprehensive Income [Abstract]
Net loss	$ (10,191,272)	$ (2,735,829)	$ (30,656,068)	$ (20,090,244)
Other Comprehensive Income (Loss), Net of Tax [Abstract]
Foreign currency translation loss	(81)	0	(1,877)	0
Unrealized loss on securities available-for-sale	(7,997)	0	(2,865)	0
Total other comprehensive loss	(8,078)	0	(4,742)	0
Total comprehensive loss	(10,199,350)	(2,735,829)	(30,660,810)	(20,090,244)
Preferred stock dividend	6,060	6,060	18,180	18,180
Comprehensive loss attributable to common stockholders	$ (10,205,410)	$ (2,741,889)	$ (30,678,990)	$ (20,108,424)

CONDENSED CONSOLIDATED STATEME6

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)	9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015
Operating activities
Net loss	$ (30,656,068)	$ (20,090,244)
Adjustments to reconcile net loss to net cash used in operating activities:
Net gain on disposal of fixed assets	0	4,562
Depreciation and amortization	693,485	250,600
Stock based compensation expense	5,942,392	2,758,847
Accretion of final fee premium	266,423	253,028
Amortization of discount on debt	105,710	59,665
Amortization of premiums on short-term investments	61,719	0
Deferred rent	(133,378)	0
Interest income accrued on short-term investments	10,122	0
Change in fair value of derivative financial instruments - warrants	(674,834)	1,105,270
Changes in operating assets and liabilities:
Decrease (increase) in other assets	2,761	(10,273)
Decrease (increase) in accounts receivable	13,584	(231,672)
Increase in prepaid expenses	(157,051)	(26,238)
Increase in accounts payable and accrued expenses	2,490,137	616,366
Net cash used in operating activities	(22,034,998)	(15,310,089)
Investing activities:
Capital expenditures, net	(797,781)	(1,256,988)
Payments for (Proceeds from) Short-term Investments	(24,451,611)	0
Net cash used in investing activities	(25,249,392)	(1,256,988)
Financing activities:
Proceeds from sales of common stock, net of expenses	2,293,857	61,215,398
Proceeds from exercise of options	366,966	818,251
Proceeds from exercise of warrants	0	1,389,427
Borrowings under equipment line of credit	792,251	0
Borrowings under long-term debt, net of costs	7,805,086	0
Repayments of long-term debt	(8,896,166)	0
Net cash provided by financing activities	2,361,994	63,423,076
Effect of exchange rate changes on cash and cash equivalents	(1,544)	0
Net change in cash and equivalents	(44,923,940)	46,855,999
Cash and cash equivalents—Beginning of period	67,493,047	27,293,798
Cash and cash equivalents—End of period	22,569,107	74,149,797
Supplementary disclosure of cash flow activity:
Cash paid for taxes	4,560	800
Cash paid for interest	806,228	795,375
Supplemental disclosure of non-cash investing and financing activities:
Preferred stock dividends accrued	18,180	18,180
Reclassification of derivative financial instruments to additional paid in capital	0	435,365
Leasehold improvements paid for by lessor	$ 1,860,000	$ 0

Organization and Basis of Prese

Organization and Basis of Presentation	9 Months Ended
	Sep. 30, 2016
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization and Basis of Presentation	Organization and Basis of Presentation Business Organization and Overview Trovagene, Inc. (“Trovagene” or the “Company”) is a molecular diagnostics company headquartered in San Diego, California. The Company’s primary focus is to leverage its cell-free DNA molecular diagnostic technology in cancer and other diseases. Trovagene's goal is to broadly commercialize its molecular diagnostic technology via direct sales as well as external license agreements and/or collaborations to democratize cancer care by establishing the best access for patient care. The Company’s proprietary Precision Cancer Monitoring® (“PCM”) platform measures circulating tumor DNA (“ctDNA”) in urine and blood, enabling personalized patient care. The Company’s PCM platform as well as urine and blood based tests, also known as liquid biopsies, have the potential to dramatically improve cancer care and usher in an era of precision oncology. Trovagene’s tests are available to clinicians for the assessment of known driver mutations in lung, pancreatic, colorectal, neuroendocrine cancers, melanoma and histiocytic disorders. The Company’s noninvasive technology provides for clinically actionable information through the detection of cancer mutations and the monitoring of changes in tumor dynamics before, during, and after treatment. Basis of Presentation The accompanying unaudited interim condensed consolidated financial statements of Trovagene, which include its wholly owned subsidiary, Trovagene, Srl, have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”). All intercompany balances and transactions have been eliminated. The accompanying unaudited interim condensed consolidated financial statements have been prepared in accordance with GAAP and the rules and regulations of the Securities and Exchange Commission (“SEC”) related to a quarterly report on Form 10-Q. Certain information and note disclosures normally included in annual financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to those rules and regulations. The unaudited interim condensed consolidated financial statements reflect all adjustments which, in the opinion of management, are necessary for a fair statement of the results for the periods presented. All such adjustments are of a normal and recurring nature. The operating results presented in these unaudited interim condensed consolidated financial statements are not necessarily indicative of the results that may be expected for any future periods. These unaudited interim condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and the notes thereto for the year ended December 31, 2015 included in the Company’s annual report on Form 10-K filed with the SEC on March 10, 2016. Liquidity Trovagene’s condensed consolidated financial statements as of September 30, 2016 have been prepared under the assumption that Trovagene will continue as a going concern. The Company’s ability to continue as a going concern is dependent upon its ability to obtain additional equity or debt financing, attain further operating efficiencies and, ultimately, to generate additional revenue. Based on current plans, the Company will be required to raise additional capital in the next twelve months to complete the development and commercialization of current product candidates and to continue to fund operations at its current projected cash expenditure levels. The Company cannot be certain that additional funding will be available on acceptable terms, or at all. To the extent that the Company can raise additional funds by issuing equity securities, the Company’s stockholders may experience significant dilution. Any debt financing, if available, may involve restrictive covenants that impact the Company’s ability to conduct its business. If the Company is unable to raise additional capital when required or on acceptable terms, it may have to significantly delay, scale back or discontinue the development and/or commercialization of one or more of its product candidates. The Company may also be required to: • Seek collaborators for product candidates at an earlier stage than otherwise would be desirable and on terms that are less favorable than might otherwise be available; and • Relinquish licenses or otherwise dispose of rights to technologies, product candidates or products that the Company would otherwise seek to develop or commercialize themselves, on unfavorable terms. The Company has approximately $44.4 million of cash, cash equivalents and short-term investments at October 31, 2016.

Summary of Significant Accounti

Summary of Significant Accounting Policies	9 Months Ended
	Sep. 30, 2016
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Summary of Significant Accounting Policies Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Revenue Recognition Revenue is recognized when persuasive evidence that an arrangement exists, delivery has occurred, the price is fixed or determinable, and collection is reasonably assured. Milestone, Royalty and License Revenues The Company licenses and sublicenses its patent rights to healthcare companies, medical laboratories and biotechnology partners. These agreements may involve multiple elements such as license fees, royalties and milestone payments. Revenue is recognized when the criteria described above have been met as well as the following: • Up-front nonrefundable license fees pursuant to agreements under which the Company has no continuing performance obligations are recognized as revenues on the effective date of the agreement and when collection is reasonably assured. • Minimum royalties are recognized as earned, and royalties in excess of minimum amounts are recognized upon receipt of payment when collection is assured. • Milestone payments are recognized when both the milestone is achieved and the related payment is received. Diagnostic Service Revenues Revenue for clinical laboratory tests may come from several sources, including commercial third-party payors, such as insurance companies and health maintenance organizations, government payors, such as Medicare and Medicaid in the United States, patient self-pay and, in some cases, from hospitals or referring laboratories who, in turn, might bill third-party payors for testing. The Company is recognizing diagnostic service revenue on the cash collection basis until such time as it is able to properly estimate collections on third party reimbursements. Derivative Financial Instruments—Warrants The Company has issued common stock warrants in connection with the execution of certain equity financings. Such warrants are classified as derivative liabilities under the provisions of Financial Accounting Standards Board (“FASB”) ASC 815 Derivatives and Hedging (“ASC 815”) and are recorded at their fair market value as of each reporting period. Such warrants do not meet the exemption that a contract should not be considered a derivative instrument if it is (1) indexed to its own stock and (2) classified in stockholders’ equity. Changes in fair value of derivative liabilities are recorded in the condensed consolidated statements of operations under the caption “Gain (loss) from change in fair value of derivative financial instruments - warrants.” The fair value of warrants is determined using the Black-Scholes option-pricing model using assumptions regarding the volatility of Trovagene’s common share price, the fair value of the underlying common shares, the remaining life of the warrant, and the risk-free interest rates at each period end. The Company thus uses model-derived valuations where inputs are observable in active markets to determine the fair value and accordingly classifies such warrants in Level 3 per ASC 820, Fair Value Measurements . At September 30, 2016 , and December 31, 2015 , the fair value of these warrants was $2,622,243 and $3,297,077 , respectively, and are recorded as a liability under the caption "Derivative financial instruments - warrants" on the balance sheet. Net Loss Per Share Basic and diluted net loss per share is presented in conformity with ASC Topic 260, Earnings per Share , for all periods presented. In accordance with this guidance, basic net loss per common share was determined by dividing net loss applicable to common stockholders by the weighted-average common shares outstanding during the period. Preferred dividends are included in income available to common stockholders in the computation of basic and diluted earnings per share. Diluted net loss per share is computed by dividing the net loss by the weighted average number of common shares and common share equivalents outstanding for the period. Common share equivalents are only included when their effect is dilutive. The following table sets forth the computation of basic and diluted earnings per share: Three Months Nine Months 2016 2015 2016 2015 Numerator: Net loss attributable to common shareholders $ (10,197,332 ) $ (2,741,889 ) $ (30,674,248 ) $ (20,108,424 ) Adjustment for (gain) loss from change in fair value of derivative financial instruments - warrants — (4,017,212 ) (533,750 ) (4,017,212 ) Net loss used for diluted loss per share $ (10,197,332 ) $ (6,759,101 ) $ (31,207,998 ) $ (24,125,636 ) Denominator for basic and diluted net loss per share: Weighted average shares used to compute basic loss per share 30,339,774 28,560,211 30,018,841 25,014,966 Adjustments to reflect assumed exercise of warrants — 568,024 117,731 189,341 Weighted average shares used to compute diluted net loss per share 30,339,774 29,128,235 30,136,572 25,204,307 Net loss per share attributable to common stockholders: Basic $ (0.34 ) $ (0.10 ) $ (1.02 ) $ (0.80 ) Diluted $ (0.34 ) $ (0.23 ) $ (1.04 ) $ (0.96 ) The following table sets forth the outstanding potentially dilutive securities that have been excluded in the calculation of diluted net loss per share because their effect was anti-dilutive: September 30, 2016 2015 Options to purchase Common Stock 6,051,186 6,514,130 Warrants to purchase Common Stock 4,546,939 4,565,947 Restricted Stock Units 392,000 — Series A Convertible Preferred Stock 63,125 63,125 11,053,250 11,143,202 Recent Accounting Pronouncements In August 2016, the FASB issued Accounting Standards Update 2016-15, Classification of Certain Cash Receipts and Cash Payments (“ASU 2016-15”), which includes amendments that clarify how certain cash receipts and cash payments are presented in the statement of cash flows. ASU 2016-15 also provides guidance clarifying when an entity should separate cash receipts and cash payments and classify them into more than one class of cash flows. The new amendments and guidance are effective for fiscal years beginning after December 15, 2017, including interim periods within those fiscal years. Early adoption is permitted provided that all amendments are adopted in the same period. The Company is currently evaluating the impact of adoption of ASU 2016-15 on its consolidated statements of cash flows. In February 2016, the FASB issued Accounting Standards Update (“ASU”) 2016-02, Leases . The new standard establishes a right-of-use (“ROU”) model that requires a lessee to record a ROU asset and a lease liability on the balance sheet for all leases with terms longer than 12 months. Leases will be classified as either finance or operating, with classification affecting the pattern of expense recognition in the income statement. The new standard is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. A modified retrospective transition approach is required for capital and operating leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements, with certain practical expedients available. The Company is currently evaluating the impact the adoption of the new standard will have on its consolidated financial statements. In August 2014, the FASB issued ASU 2014-15, Presentation of Financial Statements — Going Concern , which impacts the accounting guidance related to the evaluation of an entity’s ability to continue as a going concern. The amendment establishes management’s responsibility to evaluate whether there is substantial doubt about an entity’s ability to continue as a going concern in connection with preparing financial statements for each annual and interim reporting period. The amendment also gives guidance to determine whether to disclose information about relevant conditions and events when there is substantial doubt about an entity’s ability to continue as a going concern. The amended guidance is effective prospectively for fiscal years beginning after December 15, 2016. The new guidance is not expected to have a material impact on the Company’s financial position, results of operations or cash flows. In May 2014, the FASB issued ASU 2014-9, Revenue from Contracts with Customers (“ASU 2014-9”). ASU 2014-9 provides companies with a single model for accounting for revenue arising from contracts with customers and supersedes current revenue recognition guidance, including industry-specific revenue guidance. The core principle of the model is to recognize revenue when control of the goods or services transfers to the customer, as opposed to recognizing revenue when the risks and rewards transfer to the customer under the existing revenue guidance. The guidance permits companies to either apply the requirements retrospectively to all prior periods presented, or apply the requirements in the year of adoption, through a cumulative adjustment. In August 2015, the FASB issued ASU 2015-14, Deferral of the Effective Date , which defers the required adoption date of ASU 2014-09 by one year. As a result of the deferred effective date, ASU 2014-09 will be effective for the Company in its first quarter of fiscal year 2018. Early adoption is permitted but not before the original effective date of the first quarter of fiscal year 2017. The Company is in the process of evaluating the transition method that will be elected and the impact of adoption of ASU 2014-09 on its consolidated financial statement.

Fair Value Measurements

Fair Value Measurements	9 Months Ended
	Sep. 30, 2016
Fair Value Disclosures [Abstract]
Fair Value Measurements	Fair Value Measurements The following table presents the Company’s assets and liabilities that are measured and recognized at fair value on a recurring basis classified under the appropriate level of the fair value hierarchy as of September 30, 2016 and December 31, 2015 : Fair Value Measurements at Quoted Prices in Active Markets for Identical Assets and Liabilities (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Total Assets: Money market fund (1) $ 19,841,032 $ — $ — $ 19,841,032 Corporate debt securities (2) — 15,887,439 — 15,887,439 Commercial paper (2) — 8,489,465 — 8,489,465 Total Assets $ 19,841,032 $ 24,376,904 $ — $ 44,217,936 Liabilities: Derivative financial instruments - warrants $ — $ — $ 2,622,243 $ 2,622,243 Total Liabilities $ — $ — $ 2,622,243 $ 2,622,243 Fair Value Measurements at Quoted Prices in Active Markets for Identical Assets and Liabilities (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Total Assets: Money market fund (1) $ 65,016,222 $ — $ — $ 65,016,222 Total Assets $ 65,016,222 $ — $ — $ 65,016,222 Liabilities: Derivative financial instruments - warrants $ — $ — $ 3,297,077 $ 3,297,077 Total Liabilities $ — $ — $ 3,297,077 $ 3,297,077 (1) Included as a component of cash and cash equivalents on the accompanying condensed consolidated balance sheets. (2) Included in short-term investments on the accompanying condensed consolidated balance sheets. The following table sets forth a summary of changes in the fair value of the Company’s Level 3 liabilities for the nine months ended September 30, 2016 : Description Balance at Unrealized Gain Balance at Derivative financial instruments - warrants $ 3,297,077 $ (674,834 ) $ 2,622,243 The unrealized gain on the derivative financial instruments - warrants is recorded as a change in fair value of derivative financial instruments - warrants in the Company’s condensed consolidated statements of operations. A financial instrument’s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. At each reporting period, the Company reviews the assets and liabilities that are subject to ASC Topic 815-40. At each reporting period, all assets and liabilities for which the fair value measurement is based on significant unobservable inputs or instruments which trade infrequently and therefore have little or no price transparency are classified as Level 3.

Investments

Investments	9 Months Ended
	Sep. 30, 2016
Investments, Debt and Equity Securities [Abstract]
Investments	Investments Investments consist of corporate debt securities and commercial paper. The Company classifies debt securities as available-for-sale, as the sale of such securities may be required prior to maturity to execute management strategies. Investments classified as available-for-sale are carried at fair value, with the unrealized gains and losses reported as a component of accumulated other comprehensive income (loss) in stockholders’ equity until realized. Realized gains and losses from the sale of available-for-sale securities, if any, are determined on a specific identification basis. A decline in the market value of any available-for-sale security below cost that is determined to be other than temporary will result in an impairment charge to earnings and a new cost basis for the security is established. No such impairment charges were recorded for any period presented. Premiums and discounts are amortized or accreted over the life of the related security as an adjustment to yield using the straight-line method and included in interest income. Interest income is recognized when earned. Realized gains and losses on investments in securities will be included in other income (loss) within the condensed consolidated statements of operations. There were no realized gains and losses for the nine months ended September 30, 2016 . The following table sets forth the composition of securities available-for-sale as of September 30, 2016 . Unrealized Maturity in Years Cost Gains Losses Fair Value Corporate debt securities Less than 1 year $ 15,890,304 $ 2,162 $ (5,027 ) $ 15,887,439 Commercial paper Less than 1 year 8,489,465 — — 8,489,465 Total Investment $ 24,379,769 $ 2,162 $ (5,027 ) $ 24,376,904

Property and Equipment

Property and Equipment	9 Months Ended
	Sep. 30, 2016
Property, Plant and Equipment [Abstract]
Property and Equipment	Property and Equipment Property and equipment consist of the following: As of September 30, As of December 31, Furniture and office equipment $ 1,727,321 $ 1,483,227 Leasehold improvements 1,994,514 39,401 Laboratory equipment 2,472,444 2,022,733 6,194,279 3,545,361 Less—accumulated depreciation and amortization (1,539,403 ) (854,782 ) Property and equipment, net $ 4,654,876 $ 2,690,579

Debt

Debt	9 Months Ended
	Sep. 30, 2016
Debt Disclosure [Abstract]
Debt	Debt Equipment Line of Credit In November 2015, the Company entered into a Loan and Security Agreement (“Equipment Line of Credit”) with Silicon Valley Bank that provided for cash borrowings for equipment (“Equipment Advances”) of up to $2.0 million , secured by the equipment financed. Under the terms of the agreement, interest is equal to 1.25% above the Prime Rate. Interest only payments are due on borrowings through November 30, 2016, with both interest and principal payments commencing in December 2016. Any equipment advances after November 30, 2016 are subject to principal and interest payments immediately over a 36 -month period following the advance. All unpaid principal and interest on each Equipment Advance will be due on November 1, 2019. The Company has an obligation to make a final payment equal to 7% of total amounts borrowed at the loan maturity date. The Company is also subject to certain affirmative and negative covenants under the Equipment Line of Credit. As of September 30, 2016 , the Company was in compliance with all covenants. As of September 30, 2016 , $1,878,312 has been borrowed under the Equipment Line of Credit. As of September 30, 2016 , amounts due under the Equipment Line of Credit included $573,929 in current liabilities and $1,328,355 in long-term liabilities, which includes $23,972 of final fee premium accretion. The Company recorded $80,176 in interest expense related to the Equipment Line of Credit during the nine months ended September 30, 2016 . Future principal payments of long-term debt at September 30, 2016 are as follows: Year Ended December 31, 2016 $ 104,351 2017 626,104 2018 626,104 2019 521,753 Total principal 1,878,312 Plus final fee premium accretion 23,972 Total long-term obligations $ 1,902,284 Loan and Security Agreement In June 2014, the Company entered into a $15,000,000 loan and security agreement (“Agreement”) under which the lenders provided the Company a term loan. The loan is secured by a security interest in all of the Company’s assets except intellectual property, which is subject to a negative pledge. In connection with the loan, the lenders received a warrant to purchase an aggregate 85,470 shares of the Company’s common stock at an exercise price of $3.51 per share exercisable for ten years from the date of issuance. On July 20, 2016, the Company signed the 5th Amendment to Loan and Security Agreement (“Amendment”) to refinance its existing term loan. Under the Amendment, interest is equal to 3.75% plus the Wall Street Journal Prime Rate, subject to a floor of 7.25% . The Company is required to make interest only payments on the outstanding amount of the loan on a monthly basis through September 1, 2017, after which equal monthly payments of principal and interest are due until the loan maturity date of February 1, 2020. In addition, the lenders received a warrant to purchase an aggregate 30,992 shares of the Company’s common stock at an exercise price of $4.84 per share exercisable for ten years from the date of issuance. The fair value of the warrants, totaling $148,885 , was recorded as debt discount and additional paid-in capital as the warrants were equity classified. As of September 30, 2016 , warrants to purchase 73,727 shares of common stock remains outstanding. At the Company’s option, it may prepay all of the outstanding principal balance, subject to certain pre-payment fees ranging from 1% to 3% of the prepayment amount. In the event of a final payment of the loans under the Amendment, either in the event of repayment of the loan at maturity or upon any prepayment, the Company is obligated to pay the final fee of $1,125,000 . The Company is also subject to certain affirmative and negative covenants under the Agreement, including limitations on its ability to undergo certain change of control events, and is required to maintain its primary operating, deposit and securities accounts with the lender. In addition, the Company is required to be in compliance with healthcare laws and regulations and terms and conditions of healthcare permits. The Company was in compliance with all covenants as of September 30, 2016 . As of September 30, 2016 , amounts due under the Agreement include $227,095 in current liabilities, which include $272,905 of current portion of debt discount, and $14,267,045 in long-term liabilities, which include $76,575 of final fee premium accretion. The Company recorded $ 1,113,943 in interest expense related to the Agreement during the nine months ended September 30, 2016 . Future principal payments of long-term debt at September 30, 2016 are as follows: Year Ended December 31, 2016 $ — 2017 2,000,000 2018 6,000,000 2019 6,000,000 2020 1,000,000 Total principal 15,000,000 Less discount (582,435 ) Plus final fee premium accretion 76,575 Total long-term obligations $ 14,494,140

Derivative Financial Instrument

Derivative Financial Instruments - Warrants	9 Months Ended
	Sep. 30, 2016
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Derivative Financial Instruments - Warrants	Derivative Financial Instruments — Warrants Based upon the Company’s analysis of the criteria contained in ASC Topic 815-40, Contracts in Entity’s Own Equity, Trovagene determined that certain warrants issued in connection with the execution of certain equity financings must be recorded as derivative liabilities. In accordance with ASC Topic 815-40, the warrants are also being re-measured at each balance sheet date based on estimated fair value, and any resultant change in fair value is being recorded in the Company’s condensed consolidated statements of operations. The Company estimates the fair value of these warrants using the Black-Scholes option pricing model. The range of assumptions used to determine the fair value of the warrants valued using the Black-Scholes option pricing model during the periods indicated was: Nine Months Ended September 30, 2016 2015 Estimated fair value of Trovagene common stock 4.49-4.65 5.69-10.15 Expected warrant term 2.3-2.8 years 3.3-3.8 years Risk-free interest rate 0.71-0.87% 0.89-1.01% Expected volatility 82-90% 75-77% Dividend yield 0 % 0 % Expected volatility is based on historical volatility. The warrants have a transferability provision and based on guidance provided in SAB 107 for instruments issued with such a provision, Trovagene used the full contractual term as the expected term of the warrants. The risk free rate is based on the U.S. Treasury security rates consistent with the expected remaining term of the warrants at each balance sheet date. The following table sets forth the components of changes in the Company’s derivative financial instruments - warrants liability balance, valued using the Black-Scholes option pricing method, for the periods indicated. Date Description Number of Warrants Derivative Instrument Liability December 31, 2015 Balance of derivative financial instruments - warrants liability 967,295 $ 3,297,077 Change in fair value of derivative financial instruments - warrants during the period recognized as a gain in the condensed consolidated statements of operations — (674,834 ) September 30, 2016 Balance of derivative financial instruments - warrants liability 967,295 $ 2,622,243

Stockholders' Equity

Stockholders' Equity	9 Months Ended
	Sep. 30, 2016
Stockholders' Equity Note [Abstract]
Stockholders' Equity	Stockholders’ Equity Common Stock During the nine months ended September 30, 2016 , the Company issued a total of 861,539 shares of Common Stock. The Company received gross proceeds of approximately $2.4 million from the sale of 421,810 shares of its common stock at a weighted average price of $5.61 under the agreement with Cantor Fitzgerald & Co. (“Agent”). In addition, 98,396 shares were issued upon exercise of options for a weighted average price of $3.73 , and 341,333 shares were issued upon net exercise of 1,236,875 options at a weighted average exercise price of $3.81 . Stock Options Stock-based compensation expense related to Trovagene equity awards have been recognized in operating results as follow: Three Months Ended Nine Months Ended 2016 2015 2016 2015 Included in research and development expense $ 872,792 $ 342,122 $ 1,862,069 $ 1,054,443 Included in cost of revenue 42,639 7,518 99,164 22,468 Included in selling and marketing expense 476,865 225,892 1,493,744 480,006 Included in general and administrative expense 437,075 348,127 2,487,415 1,201,929 Total stock-based compensation expense $ 1,829,371 $ 923,659 $ 5,942,392 $ 2,758,846 The unrecognized compensation cost related to non-vested stock options outstanding at September 30, 2016 and 2015 , net of expected forfeitures, was $10,416,565 and $10,308,131 , respectively, both to be recognized over a weighted-average remaining vesting period of approximately three years . The weighted average remaining contractual term of outstanding options as of September 30, 2016 was approximately eight years . The estimated fair value of stock option awards was determined on the date of grant using the Black-Scholes option valuation model with the following weighted average assumptions during the following periods indicated: Nine Months Ended 2016 2015 Risk-free interest rate 1.48 % 1.77 % Dividend yield 0 % 0 % Expected volatility 103 % 76 % Expected term 5.5 years 6.1 years A summary of stock option activity and changes in stock options outstanding is presented below: Total Options Weighted Average Exercise Price Per Share Intrinsic Value Balance outstanding, December 31, 2015 6,948,630 $ 5.45 $ 5,903,466 Granted 3,234,750 5.02 Exercised (1,335,271 ) 3.81 Canceled / Forfeited (2,690,146 ) 5.44 Expired (106,777 ) 11.14 Balance outstanding, September 30, 2016 6,051,186 5.49 1,724,990 Exercisable at September 30, 2016 2,287,028 5.13 1,325,134 During the nine months ended September 30, 2016 , the Company had issued 996,000 options to its executive officers and non-employee directors that were over the authorized number of shares available in the Trovagene 2014 Equity Incentive Plan (2014 EIP) and were subject to shareholder approval. As per ASC Topic 815-40, the options were accounted for as liabilities and recorded at fair value with the changes in fair value being recorded in the Company’s condensed consolidated statements of operations. Stockholder approval was obtained on May 17, 2016 to increase the number of authorized shares in the 2014 EIP from 5,000,000 to 7,500,000 . Accordingly, the options were remeasured as of the date of stockholder approval with the change recorded in stock based compensation expense and the $217,333 liability was reclassified to additional paid in capital. As of September 30, 2016 there were 2,346,478 shares available for issuance under the 2014 EIP. Restricted Stock Units Under guidance provided by ASC Topic 718 “Compensation—Stock Compensation” for share-based payments, the fair value of our restricted stock units is based on the grant date fair value of our common stock. All restricted stock units were granted with no purchase price. Vesting of the restricted stock units is generally subject to service conditions, while vesting of certain units are based on attainment of specific performance objectives. The weighted-average grant date fair value of the restricted stock units was $4.06 per share during the nine months ended September 30, 2016 . There were no restricted stock units granted during the year ended December 31, 2015. A summary of the restricted stock unit activity is presented below: Number of Shares Weighted Average Grant Date Fair Value Per Share Non-vested restricted stock units outstanding, December 31, 2015 — $ — Granted 402,000 4.06 Forfeited (10,000 ) 3.99 Non-vested restricted stock units outstanding, September 30, 2016 392,000 4.06 None of the restricted stock units vested during the nine months ended September 30, 2016 . At September 30, 2016 , total unrecognized compensation cost related to non-vested restricted stock units was $537,134 , which is expected to be recognized over a weighted-average period of three months. Warrants A summary of warrant activity and changes in warrants outstanding, including both liability and equity classifications is presented below: Total Warrants Weighted Average Exercise Price Per Share Weighted Average Remaining Contractual Term Balance outstanding, December 31, 2015 5,533,242 $ 3.86 2.50 Granted 30,992 4.84 Expired (50,000 ) 8.00 Balance outstanding, September 30, 2016 5,514,234 3.82 1.85

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
	Sep. 30, 2016
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and Contingencies Executive and Consulting Agreements The Company has longer-term contractual commitments with various consultants and employees. Certain employment agreements provide for severance payments. Lease Agreements The Company previously leased approximately 22,600 square feet of office and laboratory space at a monthly rental rate of approximately $60,000 . On April 4, 2016, the Company entered into an amendment to the lease agreement which expanded the square footage of its office space to approximately 26,100 square feet at a revised monthly rental rate of approximately $68,000 . Under the amendment, the lessor provided the Company with a $1,860,000 tenant improvement allowance which the Company recorded as a deferred rent obligation. The Company will amortize the deferred rent on a straight-line basis over the life of the lease. The new lease will expire on December 31, 2021. The Company also leases certain lab and office space in Torino, Italy, of approximately 2,300 square feet, at a monthly rental rate of approximately $3,100 . The lease is for a period of three years and expires December 31, 2018. Research and Development Agreements The Company has entered into a variety of collaboration and specimen transfer agreements relating to its development efforts. Included in research and development expense, the Company has recorded approximately $0.8 million for the nine months ended September 30, 2016 relating to services provided by the collaborators in connection with these agreements. The Company is a party to various agreements under which it licenses technology on an exclusive basis in the field of human diagnostics. License fees are generally calculated as a percentage of product revenues, with rates that vary by agreement. To date, payments have not been material. The Company has entered into a collaborative research program under which it will work to design and validate custom enrichment panels--as specified by the Company. The research partner will be reimbursed for a portion of incurred costs, plus a fixed fee for target services performed. The research agreement includes an outline for a provisional commercial agreement that provides the Company with an exclusive license to use the research partner's technology in exchange for two milestone payments. The commercial agreement has not been finalized as of September 30, 2016. Public Offering and Controlled Equity Offering On May 27, 2016 the Company filed a Form S-3 Registration Statement to offer and sell in one or more offerings, any combination of common stock, preferred stock, debt securities, warrants, or units having an aggregate initial offering price not exceeding $250,000,000 . The preferred stock, debt securities, warrants, and units may be convertible or exercisable or exchangeable for common stock or preferred stock or other Trovagene securities. This form was declared effective on June 13, 2016. The Company had an agreement with Cantor Fitzgerald & Co. (“Agent”) on January 25, 2013 to issue and sell up to $30,000,000 of shares of common stock through the Agent. As payment for its services, the Agent is entitled to a 3% commission on gross proceeds. Gross proceeds of $2.4 million have been raised since the date of effectiveness of the Form S-3 on June 13, 2016. Database Usage In March 2016 the Company entered into an agreement with an outside vendor to develop an online database for test requisition and test results. Under the agreement, the Company is obligated to pay a fixed development fee, and a usage fee each time an external user completes and submits a test order form to the database. To date, the Company has paid the fixed development fee, but has incurred no costs in connection with the usage fees. Other Matters The Company may be subject to litigation or administrative proceedings related to our business, such as claims related to employment practices, commercial disputes, or patent infringement. Responding to litigation or administrative proceedings, regardless of whether they have merit, can be expensive and disruptive to normal business operations. We are not able to predict the timing or outcome of these matters.

Related Party Transactions

Related Party Transactions	9 Months Ended
	Sep. 30, 2016
Related Party Transactions [Abstract]
Related Party Transactions	Related Party Transactions In March 2016, the Company engaged Rutan & Tucker, LLP, a law firm to represent Trovagene, Inc. with respect to various lawsuits. One of the partners from Rutan & Tucker, LLP, is the son of the Company’s Chairman of the Board. The fees for legal services are based on the hourly rates of the individuals performing the legal services. As of September 30, 2016 , the Company has incurred approximately $376,000 of legal expenses for services performed by Rutan & Tucker, LLP. In September 2015, the Company entered into a research agreement with University of Turin (“University”) to collaborate on a program of research to develop, optimize and test molecular profiling tools for plasma and urine ctDNA in cancer. Dr. Alberto Bardelli, the Principal Investigator of the University who oversees this research program is also a member of the Scientific Advisory Board of the Company. Under the agreement, the Company has committed to pay up to $743,000 for the services performed by the University. In addition, the Company may pay royalties to the University on revenue generated by the Company from the commercialization of any tools developed during the collaboration. As of September 30, 2016 , the Company has incurred and recorded approximately $555,000 of research and development expenses related to the agreement. No royalty expense has been incurred as of September 30, 2016 .

Summary of Significant Accoun17

Summary of Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2016
Accounting Policies [Abstract]
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.
Revenue Recognition	Revenue Recognition Revenue is recognized when persuasive evidence that an arrangement exists, delivery has occurred, the price is fixed or determinable, and collection is reasonably assured. Milestone, Royalty and License Revenues The Company licenses and sublicenses its patent rights to healthcare companies, medical laboratories and biotechnology partners. These agreements may involve multiple elements such as license fees, royalties and milestone payments. Revenue is recognized when the criteria described above have been met as well as the following: • Up-front nonrefundable license fees pursuant to agreements under which the Company has no continuing performance obligations are recognized as revenues on the effective date of the agreement and when collection is reasonably assured. • Minimum royalties are recognized as earned, and royalties in excess of minimum amounts are recognized upon receipt of payment when collection is assured. • Milestone payments are recognized when both the milestone is achieved and the related payment is received. Diagnostic Service Revenues Revenue for clinical laboratory tests may come from several sources, including commercial third-party payors, such as insurance companies and health maintenance organizations, government payors, such as Medicare and Medicaid in the United States, patient self-pay and, in some cases, from hospitals or referring laboratories who, in turn, might bill third-party payors for testing. The Company is recognizing diagnostic service revenue on the cash collection basis until such time as it is able to properly estimate collections on third party reimbursements.
Derivative Financial Instruments-Warrants	Derivative Financial Instruments—Warrants The Company has issued common stock warrants in connection with the execution of certain equity financings. Such warrants are classified as derivative liabilities under the provisions of Financial Accounting Standards Board (“FASB”) ASC 815 Derivatives and Hedging (“ASC 815”) and are recorded at their fair market value as of each reporting period. Such warrants do not meet the exemption that a contract should not be considered a derivative instrument if it is (1) indexed to its own stock and (2) classified in stockholders’ equity. Changes in fair value of derivative liabilities are recorded in the condensed consolidated statements of operations under the caption “Gain (loss) from change in fair value of derivative financial instruments - warrants.” The fair value of warrants is determined using the Black-Scholes option-pricing model using assumptions regarding the volatility of Trovagene’s common share price, the fair value of the underlying common shares, the remaining life of the warrant, and the risk-free interest rates at each period end. The Company thus uses model-derived valuations where inputs are observable in active markets to determine the fair value and accordingly classifies such warrants in Level 3 per ASC 820, Fair Value Measurements . At September 30, 2016 , and December 31, 2015 ,
Net Loss Per Share	Net Loss Per Share Basic and diluted net loss per share is presented in conformity with ASC Topic 260, Earnings per Share , for all periods presented. In accordance with this guidance, basic net loss per common share was determined by dividing net loss applicable to common stockholders by the weighted-average common shares outstanding during the period. Preferred dividends are included in income available to common stockholders in the computation of basic and diluted earnings per share. Diluted net loss per share is computed by dividing the net loss by the weighted average number of common shares and common share equivalents outstanding for the period. Common share equivalents are only included when their effect is dilutive.
Recent Accounting Pronouncements	Recent Accounting Pronouncements In August 2016, the FASB issued Accounting Standards Update 2016-15, Classification of Certain Cash Receipts and Cash Payments (“ASU 2016-15”), which includes amendments that clarify how certain cash receipts and cash payments are presented in the statement of cash flows. ASU 2016-15 also provides guidance clarifying when an entity should separate cash receipts and cash payments and classify them into more than one class of cash flows. The new amendments and guidance are effective for fiscal years beginning after December 15, 2017, including interim periods within those fiscal years. Early adoption is permitted provided that all amendments are adopted in the same period. The Company is currently evaluating the impact of adoption of ASU 2016-15 on its consolidated statements of cash flows. In February 2016, the FASB issued Accounting Standards Update (“ASU”) 2016-02, Leases . The new standard establishes a right-of-use (“ROU”) model that requires a lessee to record a ROU asset and a lease liability on the balance sheet for all leases with terms longer than 12 months. Leases will be classified as either finance or operating, with classification affecting the pattern of expense recognition in the income statement. The new standard is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. A modified retrospective transition approach is required for capital and operating leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements, with certain practical expedients available. The Company is currently evaluating the impact the adoption of the new standard will have on its consolidated financial statements. In August 2014, the FASB issued ASU 2014-15, Presentation of Financial Statements — Going Concern , which impacts the accounting guidance related to the evaluation of an entity’s ability to continue as a going concern. The amendment establishes management’s responsibility to evaluate whether there is substantial doubt about an entity’s ability to continue as a going concern in connection with preparing financial statements for each annual and interim reporting period. The amendment also gives guidance to determine whether to disclose information about relevant conditions and events when there is substantial doubt about an entity’s ability to continue as a going concern. The amended guidance is effective prospectively for fiscal years beginning after December 15, 2016. The new guidance is not expected to have a material impact on the Company’s financial position, results of operations or cash flows. In May 2014, the FASB issued ASU 2014-9, Revenue from Contracts with Customers (“ASU 2014-9”). ASU 2014-9 provides companies with a single model for accounting for revenue arising from contracts with customers and supersedes current revenue recognition guidance, including industry-specific revenue guidance. The core principle of the model is to recognize revenue when control of the goods or services transfers to the customer, as opposed to recognizing revenue when the risks and rewards transfer to the customer under the existing revenue guidance. The guidance permits companies to either apply the requirements retrospectively to all prior periods presented, or apply the requirements in the year of adoption, through a cumulative adjustment. In August 2015, the FASB issued ASU 2015-14, Deferral of the Effective Date , which defers the required adoption date of ASU 2014-09 by one year. As a result of the deferred effective date, ASU 2014-09 will be effective for the Company in its first quarter of fiscal year 2018. Early adoption is permitted but not before the original effective date of the first quarter of fiscal year 2017. The Company is in the process of evaluating the transition method that will be elected and the impact of adoption of ASU 2014-09 on its consolidated financial statement.
Investment	Investments consist of corporate debt securities and commercial paper. The Company classifies debt securities as available-for-sale, as the sale of such securities may be required prior to maturity to execute management strategies. Investments classified as available-for-sale are carried at fair value, with the unrealized gains and losses reported as a component of accumulated other comprehensive income (loss) in stockholders’ equity until realized. Realized gains and losses from the sale of available-for-sale securities, if any, are determined on a specific identification basis. A decline in the market value of any available-for-sale security below cost that is determined to be other than temporary will result in an impairment charge to earnings and a new cost basis for the security is established. No such impairment charges were recorded for any period presented. Premiums and discounts are amortized or accreted over the life of the related security as an adjustment to yield using the straight-line method and included in interest income. Interest income is recognized when earned. Realized gains and losses on investments in securities will be included in other income (loss) within the condensed consolidated statements of operations.

Summary of Significant Accoun18

Summary of Significant Accounting Policies (Tables)	9 Months Ended
	Sep. 30, 2016
Accounting Policies [Abstract]
Schedule of Computation of Basic and Diluted Earnings per Share	The following table sets forth the computation of basic and diluted earnings per share: Three Months Nine Months 2016 2015 2016 2015 Numerator: Net loss attributable to common shareholders $ (10,197,332 ) $ (2,741,889 ) $ (30,674,248 ) $ (20,108,424 ) Adjustment for (gain) loss from change in fair value of derivative financial instruments - warrants — (4,017,212 ) (533,750 ) (4,017,212 ) Net loss used for diluted loss per share $ (10,197,332 ) $ (6,759,101 ) $ (31,207,998 ) $ (24,125,636 ) Denominator for basic and diluted net loss per share: Weighted average shares used to compute basic loss per share 30,339,774 28,560,211 30,018,841 25,014,966 Adjustments to reflect assumed exercise of warrants — 568,024 117,731 189,341 Weighted average shares used to compute diluted net loss per share 30,339,774 29,128,235 30,136,572 25,204,307 Net loss per share attributable to common stockholders: Basic $ (0.34 ) $ (0.10 ) $ (1.02 ) $ (0.80 ) Diluted $ (0.34 ) $ (0.23 ) $ (1.04 ) $ (0.96 )
Schedule of Antidilutive Securities Excluded from the Calculation of Diluted Net Loss per Share	The following table sets forth the outstanding potentially dilutive securities that have been excluded in the calculation of diluted net loss per share because their effect was anti-dilutive: September 30, 2016 2015 Options to purchase Common Stock 6,051,186 6,514,130 Warrants to purchase Common Stock 4,546,939 4,565,947 Restricted Stock Units 392,000 — Series A Convertible Preferred Stock 63,125 63,125 11,053,250 11,143,202

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	9 Months Ended
	Sep. 30, 2016
Fair Value Disclosures [Abstract]
Schedule of the Company’s Assets and Liabilities that are Measured and Recognized at Fair Value on a Recurring Basis Classified Under the Appropriate Level of the Fair Value Hierarchy	The following table presents the Company’s assets and liabilities that are measured and recognized at fair value on a recurring basis classified under the appropriate level of the fair value hierarchy as of September 30, 2016 and December 31, 2015 : Fair Value Measurements at Quoted Prices in Active Markets for Identical Assets and Liabilities (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Total Assets: Money market fund (1) $ 19,841,032 $ — $ — $ 19,841,032 Corporate debt securities (2) — 15,887,439 — 15,887,439 Commercial paper (2) — 8,489,465 — 8,489,465 Total Assets $ 19,841,032 $ 24,376,904 $ — $ 44,217,936 Liabilities: Derivative financial instruments - warrants $ — $ — $ 2,622,243 $ 2,622,243 Total Liabilities $ — $ — $ 2,622,243 $ 2,622,243 Fair Value Measurements at Quoted Prices in Active Markets for Identical Assets and Liabilities (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Total Assets: Money market fund (1) $ 65,016,222 $ — $ — $ 65,016,222 Total Assets $ 65,016,222 $ — $ — $ 65,016,222 Liabilities: Derivative financial instruments - warrants $ — $ — $ 3,297,077 $ 3,297,077 Total Liabilities $ — $ — $ 3,297,077 $ 3,297,077 (1) Included as a component of cash and cash equivalents on the accompanying condensed consolidated balance sheets. (2) Included in short-term investments on the accompanying condensed consolidated balance sheets.
Schedule of Changes in the Fair Value of the Company’s Level 3 Liabilities	The following table sets forth a summary of changes in the fair value of the Company’s Level 3 liabilities for the nine months ended September 30, 2016 : Description Balance at Unrealized Gain Balance at Derivative financial instruments - warrants $ 3,297,077 $ (674,834 ) $ 2,622,243

Investments (Tables)

Investments (Tables)	9 Months Ended
	Sep. 30, 2016
Investments, Debt and Equity Securities [Abstract]
Available-for-sale Securities	The following table sets forth the composition of securities available-for-sale as of September 30, 2016 . Unrealized Maturity in Years Cost Gains Losses Fair Value Corporate debt securities Less than 1 year $ 15,890,304 $ 2,162 $ (5,027 ) $ 15,887,439 Commercial paper Less than 1 year 8,489,465 — — 8,489,465 Total Investment $ 24,379,769 $ 2,162 $ (5,027 ) $ 24,376,904

Property and Equipment (Tables)

Property and Equipment (Tables)	9 Months Ended
	Sep. 30, 2016
Property, Plant and Equipment [Abstract]
Schedule of Components of Property and Equipment	Property and equipment consist of the following: As of September 30, As of December 31, Furniture and office equipment $ 1,727,321 $ 1,483,227 Leasehold improvements 1,994,514 39,401 Laboratory equipment 2,472,444 2,022,733 6,194,279 3,545,361 Less—accumulated depreciation and amortization (1,539,403 ) (854,782 ) Property and equipment, net $ 4,654,876 $ 2,690,579

Debt (Tables)

Debt (Tables)	9 Months Ended
	Sep. 30, 2016
Debt Disclosure [Abstract]
Future Principal Payments of Long-Term Debt	Future principal payments of long-term debt at September 30, 2016 are as follows: Year Ended December 31, 2016 $ — 2017 2,000,000 2018 6,000,000 2019 6,000,000 2020 1,000,000 Total principal 15,000,000 Less discount (582,435 ) Plus final fee premium accretion 76,575 Total long-term obligations $ 14,494,140 Future principal payments of long-term debt at September 30, 2016 are as follows: Year Ended December 31, 2016 $ 104,351 2017 626,104 2018 626,104 2019 521,753 Total principal 1,878,312 Plus final fee premium accretion 23,972 Total long-term obligations $ 1,902,284

Derivative Financial Instrume23

Derivative Financial Instruments - Warrants (Tables) - Black Scholes Option Pricing Method	9 Months Ended
	Sep. 30, 2016
Derivative financial instruments
Schedule of Assumptions Used to Determine the Fair Value of the Warrants	The range of assumptions used to determine the fair value of the warrants valued using the Black-Scholes option pricing model during the periods indicated was: Nine Months Ended September 30, 2016 2015 Estimated fair value of Trovagene common stock 4.49-4.65 5.69-10.15 Expected warrant term 2.3-2.8 years 3.3-3.8 years Risk-free interest rate 0.71-0.87% 0.89-1.01% Expected volatility 82-90% 75-77% Dividend yield 0 % 0 %
Schedule of Components of Changes in the Company’s Derivative Financial Instruments Liability Balance	The following table sets forth the components of changes in the Company’s derivative financial instruments - warrants liability balance, valued using the Black-Scholes option pricing method, for the periods indicated. Date Description Number of Warrants Derivative Instrument Liability December 31, 2015 Balance of derivative financial instruments - warrants liability 967,295 $ 3,297,077 Change in fair value of derivative financial instruments - warrants during the period recognized as a gain in the condensed consolidated statements of operations — (674,834 ) September 30, 2016 Balance of derivative financial instruments - warrants liability 967,295 $ 2,622,243

Stockholders' Equity (Tables)

Stockholders' Equity (Tables)	9 Months Ended
	Sep. 30, 2016
Stockholders' Equity Note [Abstract]
Schedule of Stock-Based Compensation Expense	Stock-based compensation expense related to Trovagene equity awards have been recognized in operating results as follow: Three Months Ended Nine Months Ended 2016 2015 2016 2015 Included in research and development expense $ 872,792 $ 342,122 $ 1,862,069 $ 1,054,443 Included in cost of revenue 42,639 7,518 99,164 22,468 Included in selling and marketing expense 476,865 225,892 1,493,744 480,006 Included in general and administrative expense 437,075 348,127 2,487,415 1,201,929 Total stock-based compensation expense $ 1,829,371 $ 923,659 $ 5,942,392 $ 2,758,846
Schedule of Assumptions to Estimate Fair Value of Stock Option Awards	The estimated fair value of stock option awards was determined on the date of grant using the Black-Scholes option valuation model with the following weighted average assumptions during the following periods indicated: Nine Months Ended 2016 2015 Risk-free interest rate 1.48 % 1.77 % Dividend yield 0 % 0 % Expected volatility 103 % 76 % Expected term 5.5 years 6.1 years
Summary of Stock Option Activity and of Changes in Stock Options Outstanding	A summary of stock option activity and changes in stock options outstanding is presented below: Total Options Weighted Average Exercise Price Per Share Intrinsic Value Balance outstanding, December 31, 2015 6,948,630 $ 5.45 $ 5,903,466 Granted 3,234,750 5.02 Exercised (1,335,271 ) 3.81 Canceled / Forfeited (2,690,146 ) 5.44 Expired (106,777 ) 11.14 Balance outstanding, September 30, 2016 6,051,186 5.49 1,724,990 Exercisable at September 30, 2016 2,287,028 5.13 1,325,134
Summary of Warrant Activity and Changes in Warrants Outstanding	A summary of warrant activity and changes in warrants outstanding, including both liability and equity classifications is presented below: Total Warrants Weighted Average Exercise Price Per Share Weighted Average Remaining Contractual Term Balance outstanding, December 31, 2015 5,533,242 $ 3.86 2.50 Granted 30,992 4.84 Expired (50,000 ) 8.00 Balance outstanding, September 30, 2016 5,514,234 3.82 1.85
Schedule of Share-based Compensation, Restricted Stock and Restricted Stock Units Activity	Under guidance provided by ASC Topic 718 “Compensation—Stock Compensation” for share-based payments, the fair value of our restricted stock units is based on the grant date fair value of our common stock. All restricted stock units were granted with no purchase price. Vesting of the restricted stock units is generally subject to service conditions, while vesting of certain units are based on attainment of specific performance objectives. The weighted-average grant date fair value of the restricted stock units was $4.06 per share during the nine months ended September 30, 2016 . There were no restricted stock units granted during the year ended December 31, 2015. A summary of the restricted stock unit activity is presented below: Number of Shares Weighted Average Grant Date Fair Value Per Share Non-vested restricted stock units outstanding, December 31, 2015 — $ — Granted 402,000 4.06 Forfeited (10,000 ) 3.99 Non-vested restricted stock units outstanding, September 30, 2016 392,000 4.06 None of the restricted stock units vested during the nine months ended September 30, 2016 . At September 30, 2016 , total unrecognized compensation cost related to non-vested restricted stock units was $537,134 , which is expected to be recognized over a weighted-average period of three months.

Organization and Basis of Pre25

Organization and Basis of Presentation - Liquidity (Details) $ in Millions	Oct. 31, 2016USD ($)
Subsequent Event
Investment [Line Items]
Cash, cash equivalents, and short-term investments	$ 44.4

Summary of Significant Accoun26

Summary of Significant Accounting Policies - Warrants (Details) - USD ($)	Sep. 30, 2016	Dec. 31, 2015
Derivative financial instruments
Derivative financial instruments - warrants	$ 2,622,243	$ 3,297,077
Warrants | Black Scholes Option Pricing Method
Derivative financial instruments
Derivative financial instruments - warrants	$ 2,622,243	$ 3,297,077

Summary of Significant Accoun27

Summary of Significant Accounting Policies - Net Loss Per Share (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Numerator:
Numerator: Net loss attributable to common shareholders	$ (10,197,332)	$ (2,741,889)	$ (30,674,248)	$ (20,108,424)
Adjustment for change in fair value of derivative financial instruments - warrants	0	(4,017,212)	(533,750)	(4,017,212)
Net loss used for diluted loss per share	$ (10,197,332)	$ (6,759,101)	$ (31,207,998)	$ (24,125,636)
Denominator for basic and diluted net loss per share:
Weighted average shares used to compute basic loss per share	30,339,774	28,560,211	30,018,841	25,014,966
Adjustments to reflect assumed exercise of warrants	0	568,024	117,731	189,341
Weighted average shares used to compute diluted net loss per share	30,339,774	29,128,235	30,136,572	25,204,307
Net loss per share attributable to common stockholders:
Net loss per common share - basic (in USD per share)	$ (0.34)	$ (0.10)	$ (1.02)	$ (0.80)
Net loss per common share - diluted (in USD per share)	$ (0.34)	$ (0.23)	$ (1.04)	$ (0.96)

Summary of Significant Accoun28

Summary of Significant Accounting Policies - Antidilutive Securities (Details) - shares	9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015
Net Loss Per Share
Antidilutive securities excluded from the calculation of basic and diluted loss per share (in shares)	11,053,250	11,143,202
Stock Option
Net Loss Per Share
Antidilutive securities excluded from the calculation of basic and diluted loss per share (in shares)	6,051,186	6,514,130
Warrants
Net Loss Per Share
Antidilutive securities excluded from the calculation of basic and diluted loss per share (in shares)	4,546,939	4,565,947
Restricted Stock Units (RSUs)
Net Loss Per Share
Antidilutive securities excluded from the calculation of basic and diluted loss per share (in shares)	392,000	0
Series A Convertible Preferred Stock
Net Loss Per Share
Antidilutive securities excluded from the calculation of basic and diluted loss per share (in shares)	63,125	63,125

Fair Value Measurements - Fair

Fair Value Measurements - Fair Value of Assets and Liabilities (Details) - USD ($)	Sep. 30, 2016	Dec. 31, 2015
Assets:
Corporate debt securities	$ 15,887,439
Short-term investments	24,376,904	$ 0
Liabilities:
Derivative financial instruments - warrants	2,622,243	3,297,077
Recurring basis
Assets:
Money market fund	19,841,032	65,016,222
Corporate debt securities	15,887,439
Total Assets	44,217,936	65,016,222
Liabilities:
Derivative financial instruments - warrants	2,622,243	3,297,077
Total Liabilities	2,622,243	3,297,077
Recurring basis | Quoted Prices in Active Markets for Identical Assets and Liabilities (Level 1)
Assets:
Money market fund	19,841,032	65,016,222
Total Assets	19,841,032	65,016,222
Recurring basis | Significant Other Observable Inputs (Level 2)
Assets:
Corporate debt securities	15,887,439
Total Assets	24,376,904
Recurring basis | Significant Unobservable Inputs (Level 3)
Liabilities:
Derivative financial instruments - warrants	2,622,243	3,297,077
Total Liabilities	2,622,243	$ 3,297,077
Commercial Paper | Recurring basis
Assets:
Short-term investments	8,489,465
Commercial Paper | Recurring basis | Significant Other Observable Inputs (Level 2)
Assets:
Short-term investments	$ 8,489,465

Fair Value Measurements - Chang

Fair Value Measurements - Changes in Fair Value of Level 3 Liabilities (Details) - Warrants	9 Months Ended
	Sep. 30, 2016USD ($)
Reconciliation of the beginning and ending balances
Balance at December 31, 2015	$ 3,297,077
Unrealized Gain	(674,834)
Balance at September 30, 2016	$ 2,622,243

Investments (Details)

Investments (Details)	Sep. 30, 2016USD ($)
Investments, Debt and Equity Securities [Abstract]
Corporate debt securities, cost	$ 15,890,304
Corporate debt securities gross unrealized gains	2,162
Corporate debt securities, unrealized loss	(5,027)
Corporate debt securities, fair value	15,887,439
Commercial paper, cost	8,489,465
Available-for-sale securities, amortized cost	24,379,769
Available-for-sale securities, fair value	$ 24,376,904

Property and Equipment (Details

Property and Equipment (Details) - USD ($)	Sep. 30, 2016	Dec. 31, 2015
Property, equipment and depreciation and amortization
Property and equipment, gross	$ 6,194,279	$ 3,545,361
Less—accumulated depreciation and amortization	(1,539,403)	(854,782)
Property and equipment, net	4,654,876	2,690,579
Furniture and office equipment
Property, equipment and depreciation and amortization
Property and equipment, gross	1,727,321	1,483,227
Leasehold improvements
Property, equipment and depreciation and amortization
Property and equipment, gross	1,994,514	39,401
Laboratory equipment
Property, equipment and depreciation and amortization
Property and equipment, gross	$ 2,472,444	$ 2,022,733

Debt - Equipment Line of Credit

Debt - Equipment Line of Credit (Details) - USD ($)	1 Months Ended	9 Months Ended
	Nov. 30, 2015	Sep. 30, 2016
Line of Credit Facility [Line Items]
Line of credit balance		$ 1,878,312
Line of credit included in current liabilities		573,929
Line of credit in long-term liabilities		1,328,355
Line of Credit [Member]
Line of Credit Facility [Line Items]
Line of credit borrowing capacity (up to)	$ 2,000,000
Principal and interest payments after advances, period	36 months
Final payment of total amounts borrowed, percentage	7.00%
Accrued final payment		23,972
Interest expenses recorded		$ 80,176
Prime Rate [Member] | Line of Credit [Member]
Line of Credit Facility [Line Items]
Interest above base rate	1.25%

Debt - Future Payments on Line

Debt - Future Payments on Line of Credit (Details) - Line of Credit [Member]	Sep. 30, 2016USD ($)
Debt Instrument [Line Items]
2,016	$ 104,351
2,017	626,104
2,018	626,104
2,019	521,753
Total principal	1,878,312
Plus final fee premium accretion	23,972
Total long-term obligations	$ 1,902,284

- Loan and Security Agreement (

- Loan and Security Agreement (Details) - USD ($)	Jul. 20, 2016	Jun. 30, 2014	Nov. 30, 2015	Sep. 30, 2016	Dec. 31, 2015	Sep. 30, 2015
Debt Instrument [Line Items]
Value of warrants recorded as debt discount and additional paid in capital				$ 148,885		$ 0
Amount borrowed included in current liabilities				801,024	$ 5,225,818
Amount borrowed, long-term liabilities				15,595,400	$ 11,246,188
Secured Debt [Member]
Debt Instrument [Line Items]
Interest expenses recorded				$ 1,113,943
Face value of term loan		$ 15,000,000
Number of common shares that can be purchased upon exercise of warrant	30,992	85,470		73,727
Exercise price of warrants (in USD per share)	$ 4.84	$ 3.51
Exercisable term of warrant	10 years	10 years
Value of warrants recorded as debt discount and additional paid in capital				$ 148,885
Amortized portion of final fee upon repayment				1,125,000
Amount borrowed included in current liabilities				227,095
Current portion of debt discount				272,905
Amount borrowed, long-term liabilities				14,267,045
Accrued final payment				76,575
Future minimum principal payments
2,016				0
2,017				2,000,000
2,018				6,000,000
2,019				6,000,000
Debt future minimum payments due in five years				1,000,000
Total principal				$ 15,000,000
Secured Debt [Member] | Minimum [Member]
Debt Instrument [Line Items]
Pre-payment fees (as a percent)				1.00%
Secured Debt [Member] | Maximum [Member]
Debt Instrument [Line Items]
Pre-payment fees (as a percent)				3.00%
Line of Credit [Member]
Debt Instrument [Line Items]
Line of credit borrowing capacity (up to)			$ 2,000,000
Principal and interest payments after advances, period			36 months
Interest expenses recorded				$ 80,176
Accrued final payment				23,972
Future minimum principal payments
Plus final fee premium accretion				23,972
Total long-term obligations				1,902,284
Line of Credit [Member] | Secured Debt [Member]
Future minimum principal payments
Less discount				(582,435)
Plus final fee premium accretion				76,575
Total long-term obligations				$ 14,494,140
Line of Credit [Member] | Secured Debt [Member] | Minimum [Member]
Debt Instrument [Line Items]
Debt instrument stated rate	7.25%
Prime Rate [Member] | Line of Credit [Member]
Debt Instrument [Line Items]
Interest above base rate			1.25%
Prime Rate [Member] | Line of Credit [Member] | Secured Debt [Member]
Debt Instrument [Line Items]
Interest above base rate	3.75%

Derivative Financial Instrume36

Derivative Financial Instruments - Warrants (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Changes in the Company's derivative financial instruments liability balance
Balance of warrants outstanding at the beginning of the period (in shares)			5,533,242
Balance of warrants outstanding at the end of the period (in shares)	5,514,234		5,514,234
Balance of derivative financial instruments liability at the beginning of the period			$ 3,297,077
Change in fair value of warrants during the period recognized as a gain in the condensed consolidated statement of operations	$ (88,208)	$ (4,017,212)	(674,834)	$ 1,105,270
Balance of derivative financial instruments liability at the end of the period	$ 2,622,243		$ 2,622,243
Warrants | Black Scholes Option Pricing Method
Range of assumptions used to determine the fair value of warrants
Dividend yield (as a percent)			0.00%	0.00%
Changes in the Company's derivative financial instruments liability balance
Balance of warrants outstanding at the beginning of the period (in shares)			967,295
Balance of warrants outstanding at the end of the period (in shares)	967,295		967,295
Balance of derivative financial instruments liability at the beginning of the period			$ 3,297,077
Balance of derivative financial instruments liability at the end of the period	$ 2,622,243		$ 2,622,243
Warrants | Black Scholes Option Pricing Method | Minimum [Member]
Range of assumptions used to determine the fair value of warrants
Estimated fair value of Trovagene common stock (in dollars per share)			$ 4.49	$ 5.69
Expected warrant term			2 years 3 months 18 days	3 years 3 months 18 days
Risk-free interest rate			0.71%	0.89%
Expected volatility (as a percent)			82.00%	75.00%
Warrants | Black Scholes Option Pricing Method | Maximum [Member]
Range of assumptions used to determine the fair value of warrants
Estimated fair value of Trovagene common stock (in dollars per share)			$ 4.65	$ 10.15
Expected warrant term			2 years 9 months 18 days	3 years 9 months 18 days
Risk-free interest rate			0.87%	1.01%
Expected volatility (as a percent)			90.00%	77.00%

Stockholders' Equity - Common S

Stockholders' Equity - Common Stock (Details) - USD ($)	9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015
Class of Stock [Line Items]
Proceeds from sales of common stock, net of expenses	$ 2,293,857	$ 61,215,398
Common Stock [Member]
Class of Stock [Line Items]
Shares of common stock issued	861,539
Option Exercise Price One [Member] | Common Stock [Member]
Class of Stock [Line Items]
Shares issued upon exercise of options (in shares)	98,396
Exercise price of stock options exercised (in USD per share)	$ 3.73
Option Exercise Price Two [Member]
Class of Stock [Line Items]
Shares issued upon exercise of options (in shares)	1,236,875
Option Exercise Price Two [Member] | Common Stock [Member]
Class of Stock [Line Items]
Exercise price of stock options exercised (in USD per share)	$ 3.81
Stock issued during period related to share options exercised	341,333
Cantor Fitzgerald And Co [Member] | Public Offering And Controlled Equity Offering | Common Stock [Member]
Class of Stock [Line Items]
Shares of common stock issued	421,810
Shares Issued, Price Per Share	$ 5.61
Proceeds from sales of common stock, net of expenses	$ 2,400,000

Stockholders' Equity - Stock-ba

Stockholders' Equity - Stock-based Compensation Expense (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Stock-based compensation expense
Total stock based compensation expense	$ 1,829,371	$ 923,659	$ 5,942,392	$ 2,758,846
Research and Development Expense
Stock-based compensation expense
Total stock based compensation expense	872,792	342,122	1,862,069	1,054,443
Cost of Revenue
Stock-based compensation expense
Total stock based compensation expense	42,639	7,518	99,164	22,468
Selling and Marketing Expense
Stock-based compensation expense
Total stock based compensation expense	476,865	225,892	1,493,744	480,006
General and Administrative Expense
Stock-based compensation expense
Total stock based compensation expense	437,075	348,127	2,487,415	1,201,929
Stock Option
Stock-based compensation expense
Unrecognized compensation cost	$ 10,416,565	$ 10,308,131	$ 10,416,565	$ 10,308,131
Weighted-average remaining vesting period for recognition				3 years
Options outstanding, weighted average contractual life			8 years

Stockholders' Equity - Stock Op

Stockholders' Equity - Stock Option Activity (Details) - USD ($)	9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	May 17, 2016	Dec. 31, 2015	Jun. 10, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share Based Compensation Number of Options Issued over Stock Option Authorized	996,000
Stock Option
Weighted-average assumptions
Risk-free interest rate	1.50%	1.77%
Dividend yield (as a percent)	0.00%	0.00%
Expected volatility (as a percent)	103.00%	76.00%
Expected term	5 years 6 months	6 years 19 days
Unrecognized compensation cost
Unrecognized compensation cost	$ 10,416,565	$ 10,308,131
Weighted-average remaining vesting period for recognition		3 years
Options outstanding, weighted average contractual life	8 years
Number of Options
Balance outstanding at the beginning of the period (in shares)	6,948,630
Granted (in shares)	3,234,750
Exercised (in shares)	(1,335,271)
Cancelled / Forfeited (in shares)	(2,690,146)
Expired (in shares)	(106,777)
Balance outstanding at the end of the period (in shares)	6,051,186
Vested and exercisable at the end of the period (in shares)	2,287,028
Weighted Average Exercise Price Per Share
Balance outstanding at the beginning of the period (in USD per share)	$ 5.45
Granted (in USD per share)	5.02
Exercised (in USD per share)	3.81
Canceled / Forfeited (in USD per share)	5.44
Expired (in USD per share)	11.14
Balance outstanding at the end of the period (in USD per share)	5.49
Vested and exercisable at the end of the period (in USD per share)	$ 5.13
Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures
Options outstanding, intrinsic value	$ 1,724,990			$ 5,903,466
Vested and exercisable at the end of the period, intrinsic value	$ 1,325,134
2014 EIP
Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures
Authorized shares under the plan			7,500,000		5,000,000
Number of remaining shares available for issuance	2,346,478
Additional Paid-in Capital
Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures
Share-based compensation option overage liability	$ 217,333

Stockholders' Equity - Restrict

Stockholders' Equity - Restricted Stock (Details) - Restricted Stock Units (RSUs)	9 Months Ended
	Sep. 30, 2016USD ($)$ / sharesshares
Number of Shares
Non-vested at beginning of period (in shares) | shares	0
Granted (in shares) | shares	402,000
Forfeited (in shares) | shares	(10,000)
Non-vested at end of period (in shares) | shares	392,000
Weighted Average Grant Date Fair Value Per Share
Nonvested, weighted average grant date fair value at beginning of period (in USD per share) | $ / shares	$ 0
Granted, weighted average grant date fair value (in USD per share) | $ / shares	4.06
Forfeited (in USD per share) | $ / shares	3.99
Nonvested, weighted average grant date fair value at end of period (in USD per share) | $ / shares	$ 4.06
Share-based compensation cost not yet recognized | $	$ 537,134
Weighted-average remaining vesting period for recognition	3 months

Stockholders' Equity - Warrants

Stockholders' Equity - Warrants (Details) - $ / shares	9 Months Ended	12 Months Ended
	Sep. 30, 2016	Dec. 31, 2014
Number of Warrants
Balance of warrants outstanding at the beginning of the period (in shares)	5,533,242
Exercised (in shares)	(50,000)
Balance of warrants outstanding at the end of the period (in shares)	5,514,234
Weighted Average Exercise Price Per Share
Weighted average exercise price of warrants at the beginning of the period (in USD per share)	$ 3.86
Exercised (in USD per share)	8
Weighted average exercise price of warrants at the end of the period (in USD per share)	$ 3.82
Term
Weighted Average Remaining Contractual Term	1 year 10 months 6 days	2 years 6 months
Class of Warrant or Right Number Granted	30,992
Class of Warrant or Right Weighted Average Exercise Price of Warrants or Rights Granted	$ 4.84

Commitments and Contingencies (

Commitments and Contingencies (Details)	Apr. 04, 2016USD ($)ft²	Nov. 30, 2015USD ($)ft²	Sep. 30, 2016USD ($)ft²
Commitments and Contingencies Disclosure [Abstract]
Area under lease (in square feet) | ft²		2,300	22,600
Monthly rental rate | $	$ 68,000	$ 3,100	$ 60,000
Deferred rent obligation | $	$ 1,860,000
Lease term		3 years
Area of land after expansion | ft²	26,100

Commitments and Contingencies -

Commitments and Contingencies - Research and Development Agreements (Details) $ in Millions	9 Months Ended
	Sep. 30, 2016USD ($)
Research and Development Arrangement | Research and Development Expense
Other Commitments [Line Items]
Revenue and license fee expense	$ 0.8

Commitments and Contingencies44

Commitments and Contingencies - Public Offering and Controlled Equity Offering and Database Usage (Details) - USD ($)	Jan. 25, 2013	Sep. 30, 2016	Sep. 30, 2016	May 27, 2016
Other Commitments [Line Items]
Proceeds from public offering		$ 2,400,000
Costs in connection with usage fees			$ 0
Public Offering And Controlled Equity Offering | Maximum [Member]
Other Commitments [Line Items]
Aggregate initial offering price				$ 250,000,000
Selling Agents [Member] | Public Offering And Controlled Equity Offering
Other Commitments [Line Items]
Commission on gross proceeds	3.00%
Selling Agents [Member] | Public Offering And Controlled Equity Offering | Maximum [Member]
Other Commitments [Line Items]
Aggregate initial offering price	$ 30,000,000

Related Party Transactions (Det

Related Party Transactions (Details)	9 Months Ended
	Sep. 30, 2016USD ($)
Affiliated Entity
Related Party Transaction [Line Items]
Legal Fees	$ 376,000
Scientific Advisory Board Member
Related Party Transaction [Line Items]
Commitment to pay for services performed, related party	743,000
Research and development expense with related party	555,000
Royalty expense	$ 0